Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 5T4 cancer vaccine; Cancer vaccine - Oxford Biomedica; Modified vaccinia Ankara 5T4; MVA-5T4; MVA-h 5T4; OBA 1 cancer vaccine; OXB-301; Recombinant modified vaccinia Ankara 5T4 vaccine; rV-5T4-VAC; SAR-109659; TroVax

Latest Information Update: 16 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oxford BioMedica
  • Developer Cardiff University; Oxford BioMedica; University College London; Wales Cancer Trials Unit
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Mesothelioma; Ovarian cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 11 Jul 2019 Discontinued - Phase-II for Colorectal cancer (Inoperable/Unresectable, Metastatic disease) in United Kingdom (IM) (Oxford BioMedica pipeline - July 2019)
  • 11 Jul 2019 Discontinued - Phase-II for Mesothelioma (Combination therapy, First-line therapy) in United Kingdom (IM) (Oxford BioMedica pipeline - July 2019)
  • 11 Jul 2019 Discontinued - Phase-II for Ovarian cancer (Early-stage disease, Mid-stage disease, Second-line therapy or greater) in United Kingdom (IM) (Oxford BioMedica pipeline - July 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top